Cytovance Biologics has completed GMP manufacture of ARMO BioSciences’ lead product, AM0010, a PEGylated form of recombinant human interleukin-10 (PEG-IL-10) being studied in advanced solid tumors.
“Cytovance is proud to have been an integral partner in the manufacture of AM0010 bulk drug substance and drug product,” said Darren Head, president and chief executive officer of Cytovance Biologics. “Our team responded to the urgency to get this important drug to patients with advanced solid tumors.”
“Cytovance’s responsive and professional team enabled us to accelerate the time to clinic of AM0010 which is currently in a Phase I dose escalation study in patients with cancer,” said Peter Van Vlasselaer, Ph.D., president and chief executive officer of ARMO. “We look forward to continuing our relationship with Cytovance as the manufacturer of product in support of the clinical development of AM0010.”